DOCSLIB.ORG

A Validated Stability-Indicating LC Method for Fluocinonide in The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

American Journal of Analytical Chemistry, 2010, 1, 113-126 doi:10.4236/ajac.2010.13015 Published Online November 2010 (http://www.SciRP.org/journal/ajac) A Validated Stability-Indicating LC Method for Fluocinonide in the Presence of Degradation Products, Its Process-Related Impurities and Identification of Degradation Products Prabha Srinivasu1,2, Devarakonda V. SubbaRao1, Raju V. K. Vegesna1, K. Sudhakar Babu2 1Versapharm Incorporated, Warminister, USA 2Department of Chemistry, Sri Krishnadevaraya University, Anantapur, India E-mail: {sreenu_ind, drdvsubbarao}@yahoo.com Received July 26, 2010; revised October 14, 2010; accepted October 27, 2010 Abstract The objective of the current study was to develop a validated, specific and stability-indicating reverse phase liquid chromatographic method for the quantitative determination of fluocinonide and its related substances. The determination was done for active pharmaceutical ingredient and its pharmaceutical dosage forms in the presence of degradation products, and its process-related impurities. The drug was subjected to stress condi- tions of hydrolysis (acid and base), oxidation, photolysis and thermal degradation per International Confer- ence on Harmonization (ICH) prescribed stress conditions to show the stability-indicating power of the method. Significant degradation was observed during acid, base hydrolysis, and peroxide degradation. The major degradants were identified by LC-MS, FTIR and 1H/13C NMR spectral analysis. The chromatographic conditions were optimized using an impurity-spiked solution and the samples generated from forced degra- dation studies. In the developed HPLC method, the resolution between fluocinonide and its process-related impurities, (namely imp-1, imp-2, imp-3, imp-4, imp-5, imp-6, imp-7 and imp-8) and its degradation products was found to be greater than 2.0. The chromatographic separation was achieved on a C18, 250 mm × 4.6 mm, 5 µm column. The LC method employed a linear gradient elution and the detection wavelength was set at 240 nm. The stress samples were assayed against a qualified reference standard and the mass balance was found to be close to 99.3%. The developed RP-LC method was validated with respect to linearity, accuracy, precision and robustness. Keywords: Fluocinonide, RP-LC, LC-MS, Forced Degradation, Validation, Stability-Indicating 1. Introduction a “high-potency” (second-highest rank) topical cortico- steroid [1]. Corticosteroids have multiple actions, in- Fluocinonide, pregna-1, 4-diene-3, 20-dione, 21-(acety- cludeing anti-inflammatory and anti-proliferative effects. loxy)-6, 9-difluoro-11-hydroxy-16, 17-[(1-methylethyli- When applied topically for at least one week, fluocinon- dene)bis(oxy)]-, (6α, 11β, 16α)-, is a potent glucorticoid ide is effective in the treatment of inflammation and steroid used topically as anti-inflammatory agent for the itching caused by a number of skin conditions such as treatment of skin disorders such as eczema. It relieves allergic reactions, eczema and psoriasis. Minimal amounts itching, dryness, redness, crusting, scaling, inflammation should be used for a minimal length of time to avoid the and discomfort. Fluocinonide is a white or almost white occurrence of adverse effects. Fluocinonide is also used crystalline powder. It is practically insoluble in water; in veterinary medicine. It is used for treatment of aller- slightly soluble in absolute ethanol. There are seven gies in dogs. Natural systemic cortisol concentrations can classes of topical corticosteroids ranked according to be suppressed for weeks after one week of topical expo- their potency based vasoconstrictor assays. Fluocinonide sure. is a fluorinated, highly potent, corticosteroid. It ranks as A chromatographic assay method has appeared in US Copyright © 2010 SciRes. AJAC 114 P. SRINIVASU ET AL. pharmacopeia for the quantification of fluocinonide in Fluocinonide drug substance and its pharmaceutical topical dosage O forms [2]. Few analytical methods were available in lit- O 22 erature for the quantification of fluocinonide and fluclo- 21 23 cortisone acetate. Shek E. et al. has described an HPLC 25 20 procedure to chromatograph fluocinonide as well as tri- 19 O 12 amcinolone acetonide and diflorasone diacetate [3-6]. In HO 17 O 24 addition, Shek E. et al. reported the stability indicating 11 13 18 26 16 O LC method for triple corticoid integrated system in a 1 9 14 cream. [3] in which Shek. E. et al. described the quanti- 2 8 10 15 fication of–fluocinonide, procinonide and ciprocinonide F and expected the major degradation product under hy- 3 5 7 6 drolytic conditions would be fluocinolone acetonide. O 4 Further study was not carried out to confirm this impu- rity. The present study was carried out to describe de- F tailed degradation studies as per ICH guidelines and de- (a) pregna-1, 4-diene-3, 20-dione, 21-(acetyloxy)-6, 9-difluoro-11- hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 16α)-. Mo- veloped a suitable LC method for the separation and es- lecular weight: 494.52. timation of both process related impurities and degrada- tion impurities. Interestingly author observed two major Imp-1 degradation products in acid, base hydrolysis and perox- OH ide degradation of fluocinonide. The major degradation 21 products of fluocinonide were isolated using preparative HPLC and structure elucidation was performed for the 19 O same using advanced spectral techniques such as NMR, 20 12 17 OH LC-MS and IR. The purpose of the present research HO 11 13 work was to develop a suitable single stability-indicating 18 16 LC method for the determination of fluocinonide and its OH 1 9 related substances and structure elucidation of major 14 2 8 degradation products. The developed LC method was 10 15 validated with respect to specificity, LOD, LOQ, linear- F 3 5 ity, precision, accuracy and robustness. Forced degrada- 7 6 tion studies were performed on the drug substance and O 4 drug products to show the stability-indicating nature of the method [7-13]. These studies were performed in ac- F cordance with established ICH guidelines [14-15]. (b) pregna-1, 4-diene-3, 20-dione, -6, 9-difluoro-11, 16, 17, 21- tetrahydroxy-, (6α, 11β, 16α)-. Molecular weight: 412.42. 2. Experimental Imp-2 OH H3CO 2.1. Chemicals 22 21 24 Samples of fluocinonide and its related impurities were 19 20 O 12 23 received from Versapharm Incorporated, Warminister, HO 17 O PA, USA. (Figure 1). All of the impurities and the fluo- 11 13 18 25 cinonide standard were of > 90% purity and are as fol- 16 O lows:-, fluocinonide (99.6%), imp-1 (95.9%), imp-2 1 9 2 8 14 (99.3%), imp-3 (93.7%), imp-4 (99.5%) imp-5 (96.7%), 10 15 imp-6 (98.5%), imp-7 (97.8%) and imp-8 (99.2%). F 3 5 Commercially available fluocinonide ointment and fluo- 7 O 6 cinonide solution (LIDEX) were purchased for this study. 4 In addition, HPLC grade acetonitrile and methanol were F purchased from Merck, (Darmstadt, Germany). Analyti- (c) pregna-1, 4-diene-3, 20-dione, -6, 9-difluoro-11, 21-dihydroxy- cal reagent grade sodium dihydrogen phosphate mono- 21methoxy-16, 17-[(1-methylethylidene)bis(oxy)]-(6α, 11β, 16α) Mo- hydrate, phosphoric acid and acetic acid were purchased lecular weight: 482.51. Copyright © 2010 SciRes. AJAC P. SRINIVASU ET AL. 115 Imp-3 Imp-6 O OH O 21 22 23 23 21 19 20 O 25 22 19 20 HO 12 17 O O 12 24 HO 17 O 18 11 13 16 24 O 11 13 18 16 26 1 9 O 1 9 2 8 14 10 15 8 14 2 15 F 10 3 5 F 6 7 3 5 7 O 6 4 O 4 F F (d) pregna-1, 4-diene-3, 20-dione, -6, 9-difluoro-11, 21-dihydroxy-16, (g) pregna-1, 4-diene-3, 20-dione, 21-(acetyloxy)-6, 9-difluoro-11- 17-[(1-methylethylidene)bis(oxy)]-, (6β, 11β, 16α)-. Molecular weight: hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (6β, 11β, 16α)-. Mo- 452.49. lecular weight: 494.52. Imp-7 Imp-4 O OH O 21 22 23 23 21 19 20 O 25 22 19 20 12 17 O O 12 24 11 HO 17 O 18 O 13 16 24 O 11 13 18 16 26 1 O 1 9 8 14 9 2 14 10 15 2 8 10 15 3 5 F 6 7 3 5 O 4 7 4 O 6 F F (e) pregna-1, 4-diene-3, 20-dione, -6-fluoro-9, 11 epoxy, -21- (h) pregna-1, 4-diene-3, 20-dione, 21-(acetyloxy)-4, 9-difluoro-11- hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 16α)-. Mo- hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (4α, 11β, 16α)- Mo- lecular weight: 432.48. lecular weight: 496.54. Imp-8 Imp-5 O OH O 21 23 21 19 20 O 25 22 19 20 HO 12 17 O O 12 24 HO 17 O 18 11 13 16 24 O 11 13 18 16 26 1 9 O 8 14 1 9 2 15 10 2 8 14 F 10 15 3 5 F 6 7 3 5 7 O 6 4 O 4 Cl Cl (f) pregna-1, 4-diene-3, 20-dione, -6 chloro, 9-fluoro-11, 21-dihydroxy- (i) pregna-1, 4-diene-3, 20-dione, 21-(acetyloxy)-6-Chloro, 9-fluoro- 16, 17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 16α)-. Molecular 11-hydroxy-16, 17-[(1-methylethylidene)bis(oxy)]-, (6α, 11β, 16α)-. Mo- weight: 468.94. lecular weight: 510.18. Copyright © 2010 SciRes. AJAC 116 P. SRINIVASU ET AL. Degradation (Base degradation) impurity at RRT 0.54 2.3. Chromatographic Conditions O O A Waters symmetry C18 250 mm × 4.6 mm, 5 µm col- 22 21 umn was used with a mobile phase containing a gradient 23 of solvents A and B.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate

    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
  • 1522 Corticosteroids

    1522 Corticosteroids

    1522 Corticosteroids Oral bioavailability is less than 1%. Ciclesonide and its Clobetasol Propionate (BANM, USAN, rINNM) ⊗ X; Clodavan; Cortopic; Dermovate; Koniderm; Lobevat†; Xinder; Cz.: Clobex; Dermovate; Denm.: Dermovat; Fin.: Dermovat; Fr.: Dermoval; active metabolite are extensively bound to plasma pro- CCI-4725; Clobétasol, propionate de; Clobetasoli propionas; Ger.: Clobegalen; Dermoxin; Dermoxinale; Karison; Gr.: Butavate; Clare- teins. It is further metabolised to inactive metabolites lux; Rubocort; Hong Kong: Clobasol; Clobesol; Clobex; Dermasone†; GR-2/925; Klobetasol-propionát; Klobetazol Propiyonat; Dermo; Dermovate; Dhabesol; Eurobetsol; Medodermone; Uniderm; via the cytochrome P450 isoenzyme CYP3A4. After Klobetazolu propionian; Propionato de clobetasol. 21-Chloro- Hung.: Closanasol; Dermovate; India: Cloderm; Lobate; Tenovate; Topi- oral or intravenous dosage, ciclesonide is mainly ex- 9α-fluoro-11β,17α-dihydroxy-16β-methylpregna-1,4-diene- fort; Indon.: Bersol; Closol; Dermovate; Elopro; Forderm; Ikaderm; Kloder- ma; Klonat; Lamodex; Lotasbat; Primaderm; Psoriderm; Irl.: Dermovate; creted via the faeces. 3,20-dione 17-propionate. Israel: Dermovate; Ital.: Clobesol; Malaysia: Betasol†; Clobet; Cloderm; Dermapro†; Dermosol; Dermovate; Dhabesol; Lobesol†; Uniderm; Uni- ◊ References. Клобетазола Пропионат vate†; Mex.: Clobesol; Dermatovate; Lobevat; Neth.: Clarelux; Clobex; C H ClFO = 467.0. Dermovate; Olux†; Norw.: Dermovat; NZ: Dermol; Philipp.: Clonate; 1. Rohatagi S, et al. Population pharmacokinetics and pharmacody- 25 32 5 Closderm; Dermovate; Glevate; Pol.: Clobederm; Dermklobal; Dermo- namics of ciclesonide. J Clin Pharmacol 2003; 43: 365–78. CAS — 25122-41-2 (clobetasol); 25122-46-7 (clobetasol vate; Novate; Port.: Clarelux; Dermovate; Etrivex; Rus.: Dermovate propionate). (Дермовейт); S.Afr.: Dermovate; Dovate; Xenovate; Singapore: 2. Nave R, et al. Pharmacokinetics of [ C]ciclesonide after oral Clobeson†; Cloderm; Dermosol; Dermovate; Dhabesol; Medodermone; and intravenous administration to healthy subjects.
  • Seasonal Allergies and Atopic Dermatitis: a Missing Link?

    Seasonal Allergies and Atopic Dermatitis: a Missing Link?

    COVER FOCUS Seasonal Allergies and Atopic Dermatitis: A Missing Link? Evidence increasingly suggests that dermatologists need to watch for allergens in AD—from the interaction between environmental allergens and eczema to corticosteroid allergy. BY LEON H. KIRCIK, MD AND JAMES Q. DEL ROSSO, DO ommon seasonal allergy symptoms—itchy eyes, creating buzz not only about corticosteroids in general runny noses, and scratchy throats—lead many but also their cross-reactivity among themselves.3 Table patients to visit an allergist, but a growing num- 1 shows five core structural classes: A, B, C, D1, and D2. ber are seeking help at dermatologists’ offices as Cross-reactivity issues spark the need to screen patients Cwell. Allergen exposure through the skin may initiate sys- temic allergies especially, in patients who are predisposed TAKE HOME TIPS to atopic dermatitis (AD), allergic rhinitis, and asthma.1,2 While many dermatologists may be aware of this research, Allergen exposure through the skin may initiate systemic the implications for patient care may be less obvious. allergies especially, in patients who are predisposed to atopic Airborne allergens from pollen, trees, grass, plants, and dermatitis (AD), allergic rhinitis, and asthma. Airborne ragweed can cause these typical allergic reactions, and the allergens from pollen, trees, grass, plants, and ragweed can heightened systemic response to allergens may instigate a cause typical allergic reactions, and the heightened systemic flare of AD. Furthermore, contact allergy or other cutaneous response to allergens may instigate a flare of AD; contact reactions can also result when allergens comes into contact allergy or other cutaneous reactions can also result when with the skin.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • Corticotropin(BAN, Rinn) ⊗

    Corticotropin(BAN, Rinn) ⊗

    Ciprocinonide/Corticotropin 1523 Clocortolone Pivalate (USAN, rINNM) ⊗ Corticorelin (rINN) ⊗ ma-cortisol concentrations in response to corticorelin, whereas those with adrenal or ectopic syndrome generally have no re- CL-68; Clocortolone, Pivalate de; Clocortoloni Pivalas; Pivalato Corticoliberin; Corticorelina; Corticoréline; Corticorelinum; sponse.3,4 The corticorelin stimulation test is of comparable diag- de clocortolona; SH-863. 9α-Chloro-6α-fluoro-11β,21-dihy- Corticotrophin-releasing Hormone; Corticotropin-releasing nostic efficacy to the dexamethasone suppression test,5,6 al- droxy-16α-methylpregna-1,4-diene-3,20-dione 21-pivalate. Factor; CRF; CRH; HLC; Hormona liberadora de corticotropina. though false results have been obtained with both tests.2,5,7 Клокортолона Пивалат Кортикорелин Again, a combination of the dexamethasone and corticorelin 6 C27H36ClFO5 = 495.0. C208H344N60O63S2 = 4757.5 (human); tests is reportedly more accurate than either alone. The most re- CAS — 4828-27-7 (clocortolone); 34097-16-0 (clocor- C205H339N59O63S = 4670.3 (ovine). liable test to distinguish between pituitary and nonpituitary forms tolone pivalate). CAS — 86784-80-7 (corticorelin (human)); 79804-71-0 of Cushing’s syndrome is to measure the difference between cen- ATC — D07AB21. (corticorelin (ovine)). tral and peripheral concentrations of ACTH after giving corti- 2 ATC Vet — QD07AB21. ATC — V04CD04. corelin. However, this requires sampling of central (petrosal) ATC Vet — QV04CD04. venous blood, an invasive procedure needing considerable ex- pertise. 1. Yanovski JA, et al. Corticotropin-releasing hormone stimulation CH3 Corticorelin Triflutate (rINNM) ⊗ H C CH following low-dose dexamethasone administration: a new test to 3 3 Corticorelin Trifluoroacetate; Corticoréline, Triflutate de; Corti- distinguish Cushing’s syndrome from pseudo-Cushing’s states.
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al

    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
  • Ited States Patent (10) Patent N0.: US 7,271,274 B2 Meng Et A]

    Ited States Patent (10) Patent N0.: US 7,271,274 B2 Meng Et A]

    US007271274B2 (12) United States Patent (10) Patent N0.: US 7,271,274 B2 Meng et a]. (45) Date of Patent: Sep. 18, 2007 (54) PHENOLIC ANTIOXIDANTS FOR THE 6,881,860 B2 4/2005 Sikorski et al. TREATMENT OF DISORDERS INCLUDING 2002/0193446 A1 12/2002 Meng ARTHRITIS, ASTHMA AND CORONARY 2003/0064967 A1 4/2003 Luchoomun et al. ARTERY DISEASE 2004/0266879 A1 12/2004 Sikorski et al. 2005/0065121 A1 3/2005 Sikorski et al. (75) Inventors: Charles Q. Meng, Duluth, GA (US); i/(fmers M. David. WeIngarten,. Cummmg,. GA eng et a1. (Us) FOREIGN PATENT DOCUMENTS (73) Assignee: AhteroGenics, Inc., Alpharetta, GA EP 0 348 203 A1 12/1989 (Us) EP 0 405 788 A2 1/1991 EP 0 621 255 A1 10/1994 ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (Continued) USC‘ 1540’) by 0 days‘ OTHER PUBLICATIONS (21) Appl. NO-Z 11/111,196 Barnhart, J.W., et al., “Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs,” Pharmacochem. (22) Filed: Apr. 20, 2005 Lib/1, in Antilipidemic Drugs: Medicinal, Chemical, and Biochemi cal Aspects, Witiak et al., Eds., (Elsevier Science: Amsterdam, (65) Prior Publication Data 1991), pp. 277-299. Baron, J .L., et al., “The pathogenesis of adoptive murine autoim US 2006/0020038 A1 Jan' 26> 2006 mune diabetes requires an interaction between a4-integrins and vascular cell adhesion molecule-1,” J. Clin. Invest, 93(4-6):1700 Related US. Application Data 1703 (1994), (60) Provisional application No. 60/600,029, ?led on Aug.